Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Puzo Michael J

Puzo Michael J raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 8.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,285 shares of the pharmaceutical company's stock after purchasing an additional 1,176 shares during the period. Vertex Pharmaceuticals comprises about 2.1% of Puzo Michael J's portfolio, making the stock its 26th largest holding. Puzo Michael J's holdings in Vertex Pharmaceuticals were worth $7,410,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mascagni Wealth Management Inc. acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at approximately $31,000. Truvestments Capital LLC lifted its stake in Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after buying an additional 23 shares during the last quarter. Mpwm Advisory Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at $40,000. Midwest Capital Advisors LLC bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $41,000. Finally, Minot DeBlois Advisors LLC bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $44,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Down 2.0%

Shares of Vertex Pharmaceuticals stock opened at $441.99 on Wednesday. The firm has a market cap of $113.50 billion, a price-to-earnings ratio of -112.75 and a beta of 0.41. The stock has a 50-day simple moving average of $461.30 and a 200-day simple moving average of $459.86. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. During the same quarter last year, the firm earned $4.76 earnings per share. Vertex Pharmaceuticals's revenue was up 2.6% compared to the same quarter last year. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the subject of a number of analyst reports. Scotiabank reduced their target price on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group reiterated a "buy" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Erste Group Bank lowered Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Wolfe Research downgraded Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Finally, Wall Street Zen upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, March 11th. Fourteen research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $513.32.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.